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region candidate 1 · Deficiency of adenosine deaminase 2 · 
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Abstract
Background: The association that exists between livedo re-
ticularis (LR) and stroke is known as Sneddon’s syndrome 
(SnS). The disorder is classified as primary SnS (PSnS), if the 
cause remains unknown and secondary SnS. The condition 
is rare and it occurs mainly sporadically. In 2014, 2 indepen-
dent teams described a new genetic disorder with child-
hood-onset, which was called deficiency of adenosine de-
aminase 2 (DADA2), characterized by recurrent fevers and 
vascular pathologic features that included LR and stroke. All 
the patients carried recessively inherited mutations in cat 
eye syndrome chromosome region candidate 1 gene 
(CECR1), encoding the adenosine deaminase 2 (ADA2) pro-
tein. Genetic testing is the standard for the diagnosis of 
DADA2. However, the diagnostic accuracy of more afford-
able laboratorial analysis in CECR1-mutated individuals re-
mains to be established. We aim to determine whether plas-
ma ADA2 activity and serum immunoglobulin M (IgM) levels 
can distinguish (1) DADA2 from other adult patients within 
the SnS spectrum, and (2) healthy CECR1 heterozygous (HHZ) 
from healthy controls (HC). Methods: ADA2 activity in plas-
ma and serum IgM concentrations was measured in adult 
patients within the SnS spectrum, healthy first-degree rela-
tives and HC. Genetic results were used as the reference stan-
dard. The primary outcome measures were sensitivity and 
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specificity derived from receiver operating curve analysis. 
Results: A total of 73 participants were included in the study: 
26 patients with PSnS with no CECR1 mutation (PSnS), 6 bi-
allelic (DADA2 patients) and 7 HHZ CECR1 mutations and 34 
HC. Plasma ADA2 activity and serum IgM levels were signifi-
cantly lower in DADA2 patients than in PSnS. With the use of 
the best indexes, plasma ADA2 activity differentiated PSnS 
from DADA2 with a sensitivity and specificity of 100.0% and 
HHZ from HC with a sensitivity of 97.1% and specificity of 
85.7%. Serum IgM levels also differentiated PSnS from 
DADA2 with a sensitivity of 85.2% and specificity of 83.3%. 
Conclusion: Serum IgM levels might be used as a triage tool 
and plasma ADA2 activity performs perfectly as a diagnostic 
test for DADA2 in adult patients within the SnS spectrum. 
ADA2 activity in plasma also reliably distinguishes HHZ from 
HC. © 2019 S. Karger AG, Basel
Introduction
The association that exists between livedo reticularis 
(LR) and stroke is known as Sneddon’s syndrome (SnS) 
[1].
The disorder is classified as primary SnS (PSnS) if the 
cause remains unknown, or secondary SnS, which usu-
ally occurs as part of well-known autoimmune disorders 
(antiphospholipid syndrome with/without coexisting 
systemic lupus erythematous) [2].
SnS is rare and it occurs mainly sporadically [3]. In 
2014, 2 independent teams [4, 5] described a new genetic 
disorder with childhood-onset, which was called Defi-
ciency of adenosine deaminase (DADA2), characterized 
by recurrent fevers and vascular pathologic features that 
included LR and stroke. All the patients carried reces-
sively inherited mutations in Cat Eye Syndrome Chro-
mosome Region Candidate 1 gene (CECR1), encoding 
the adenosine deaminase 2 (ADA2) protein. Laboratory 
manifestations included reduced active ADA2 concen-
tration in plasma and mild immunodeficiency. In the 
same year, Bras et al. [6] identified a compound hetero-
zygous missense mutation in CECR1 in a Portuguese SnS 
family with adult onset, previously reported in 2002 [7, 
8], expanding the phenotype associated with mutations 
in this gene to include later onsets of disease.
Genetic testing is the standard for the diagnosis of 
DADA2. However, the diagnostic accuracy of more af-
fordable laboratorial analysis in CECR1 mutated individ-
uals remains to be established. The purpose of this study 
was therefore to determine whether plasma ADA2 activ-
ity and serum immunoglobulin M (IgM) levels can dis-
tinguish DADA2 from other adult patients within the SnS 




All consecutive individuals within SnS’s spectrum were collect-
ed in a prospective longitudinal database and full written informed 
consent was obtained from all participants. The study protocol was 
approved by the local Ethics Committee (Faculdade de Medicina 
da Universidade de Coimbra, Proc. CE-126/2015, approved No-
vember 30, 2015). The majority of participants were identified lo-
cally, in a tertiary University Hospital in Portugal. Three were re-
ferred by the National Amyloidosis Centre, UCL Division of Med-
icine, London.
Inclusion criteria were as follows: patients aged 18 years or old-
er with SnS, both sporadic or familial; patients with LR and family 
history of SnS; healthy volunteers who were first-degree relatives 
of patients with familial SnS. We also included healthy volunteer 
individuals recruited by advertisement. Controls had no relation-
ship with the other participants and no history of LR, cerebrovas-
cular disease or other neurological illness.
SnS was defined by the association of a widespread LR involv-
ing the trunk and/or the buttock and/or the legs and at least one 
clinical cerebral event (either ischemic or haemorrhagic stroke, 
transient ischemic attack or a silent vascular brain lesion detected 
on MRI). Patients were excluded if they presented: (1) at least one 
of the clinical criteria and one of the laboratory criteria for An-
tiphospholipid antibody syndrome [9] and/or (2) clinical and im-
munological criteria for Systemic Lupus Erythematous [10] or (3) 
any thrombophilic state.
Demographic and clinical features, including vascular risk fac-
tors and laboratorial data, were collected from all participants in a 
standardized format.
All the technicians involved in the study were blinded for the 
clinical features and any other laboratorial results.
Procedures
Total ADA and ADA2 Activity in Plasma
Blood samples were collected from all participants into lithi-
um heparin tubes. The tubes were centrifuged at 1,500 g at 4  ° C 
for 10 min and plasma was separated and frozen at –80  ° C until 
analysis.
Total ADA-T was determined through a commercial method 
(Diazyme) based on the conversion of adenosine into inosine and 
further into hypoxanthine (by purine nucleoside phosphorylase) 
and into uric acid and hydrogen peroxide (by xanthine oxidase). The 
conversion of hydrogen peroxide by peroxidase into the quinone 
dyes 4-aminoantipyrine and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-
m-toluidine was then monitorized at 550 nm in a thermostatized 
spectrophotometer at 37  ° C (UVIKON 933 UV/Visible). ADA2 ac-
tivity was measured by the same method, in the presence of 0.1 mM 
of erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA, 
Sigma), a potent selective inhibitor of ADA1 [11]. ADA1 activity was 
then calculated by subtracting ADA2 activity from total ADA activ-
ity.
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Each sample was run in duplicate and 2 control samples 
(with high and low levels of ADA activity) were assayed in each 
day for internal quality control. The intra-assay coefficient vari-
ation, calculated from 6 repeats, was 6.4%, and the inter-assay 
coefficient variation, calculated for 13 runs performed, was 
5.5%.
Quantitative Assessment of Serum IgM 
A nephelometric method was used for the measurement of IgM 
levels in serum samples, using the same technical conditions (per-
formed on the same day and working session, and using the same 
batch of reagents, N ASIGM, Siemens HDP). The IgM contained 
in the human serum form immune complexes with specific anti-
bodies that are present in the reagent. These complexes scatter a 
beam of light passed through the sample and the intensity of the 
scattered light is proportional to the concentration of IgM in the 
sample [12]. The results were then evaluated by comparison with 
a standard of known concentration.
Genetic Analyses
DNA was extracted according to manufacturer’s instructions 
from saliva samples collected using the Oragene DNA (OG-500, 
DNA Genotek) kit or from blood samples using the GE Healthcare 
NucleonTM BACC3 Genomic DNA Extraction Kit. Exome and 
Sanger sequencing were used to identify mutations and variants in 
the CECR1 gene in all the patient’s groups studied.
Exome sequencing was initially performed in 2 siblings from a 
Portuguese SS family and results were reported in Bras et al. [6] 
Exome sequencing was also performed in 14 Portuguese addition-
al cases (4 familial and 10 sporadic) by preparing genomic DNA 
and capturing it using Agilent’s SureSelect version 4 capture kit, 
according to manufacturer’s instructions. Sequencing was per-
formed in Illumina’s HiSeq2000 using 100 bp paired-end reads 
and data were analyzed after quality control and following stan-
dard procedures (online suppl. data; for all online suppl. material, 
see www.karger.com/doi/10.1159/000495794). Variants in CECR1 
were extracted and compared to databases of human genetic vari-
ability.
Sanger sequencing was used in the remaining samples. For this, 
primers for all exons of CECR1 were designed using Primer3. De-
tails for the PCR conditions, electrophoresis of PCR products and 
Sanger sequencing procedures used and primer design are pro-
vided in the online supplementary material. Sanger sequencing of 
CECR1 was also performed in the 3 patients that were referred by 
the National Amyloidosis Centre, UCL Division of Medicine, Lon-
don. This was done at Great Ormond Street Hospital’s Foundation 
Trust, using standard procedures.
Statistical Analysis
The results of genetic testing were the reference standard for 
the diagnosis of DADA2.
Baseline characteristics are presented as frequency (percent-
age) for dichotomous variables and mean ± SD for continuous 
variables.
A 2-way Mann-Whitney U test was used to compare means 
between groups. 
Area under the curve (AUC) for receiver operating character-
istic (ROC) analysis was used to determine diagnostic accuracy 
(sensitivity, specificity, positive and negative predictive values, ac-
curacy) for both tests (serum IgM levels and plasma ADA2 activ-
ity) with 95% CI. Cut-off points were set to minimize the difference 
between sensitivity and specificity (Youden index). Statistical sig-
nificance was assumed at p < 0.05.
Results
Participants and Laboratorial Parameters
Between January 2, 2016 and December 23, 2017, we 
screened 96 potential individuals; 73 of them (mean age 
41.5 ± 11.0, male 31.5%) met the inclusion criteria and 
were therefore enrolled in the study. Four subjects did not 
consent to participate and 19 were excluded as they had 
secondary SnS. Twenty-six patients with no CECR1 mu-
tation (age 45.1 ± 9.8), 6 bi-allelic (DADA2 patients; age 
41.7 ± 12.1) and 7 HHZ CECR1 mutated individuals (age 
32.0 ± 13.9) and 34 HC (age 40.6 ±10.2) were included in 
the study (Fig. 1). The CECR1 mutations identified in the 
cohort studied and the coding variants identified in the 
individuals without CECR1 mutations are shown in on-
line supplementary Tables S2, and S3 respectively.
General demographic and clinical characteristics of 
the study population are presented in Table 1.
Total ADA, ADA2 and ADA1 activities, as well as serum 
IgM levels of the studied population are shown in Table 2. 
DADA2 patients had significantly lower serum IgM levels 
(p = 0.002), as well as significantly reduced activity of total 
ADA (p < 0.001) and ADA2 (p < 0.001) compared to PSnS 
patients. In fact, ADA2 activity was almost completely abol-
ished in bi-allelic mutation carriers, ranging from 0 to 0.34 
U/L and showing no overlap with patients without muta-
tion (range 5.15–25.41 U/L; Fig. 2b). For IgM, although a 
statistically significant difference was seen, still some over-
lap between groups remained (Fig. 2a). In HHZ, IgM levels 
were not significantly different from HCs (p = 0.225; 
Fig. 2a); however, a significant reduction of both total ADA 
and ADA2 activity was seen (p = 0.004 and p < 0.001, respec-
tively, vs. HC). The reduction in ADA2 activity in HHZ was 
not as strong as in DADA2 patients (activity levels ranging 
between 1.50 and 5.62 U/L), and therefore some overlap 
with activity levels determined in HCs was detected (Fig. 2b). 
No statistical differences were found in mean IgM levels or 
total ADA and ADA2 activity between PSnS and HC. ADA1 
activity was similar between all groups.
Diagnostic Accuracy of Plasma ADA2 Activity and 
Serum IgM Levels
Differentiating DADA2 from PSnS
An ROC curve was plotted to compare how effectively 
plasma ADA2 activity and serum IgM levels distinguished 
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patients with DADA2 from PSnS (Fig. 3a). Accuracy pa-
rameters for this distinction are shown in Table 3. For 
serum IgM levels, at the best cut-off of 0.65 g/L, the AUC 
was 0.904 (95% CI 0.775–1.000), sensitivity of 85.2%, and 
specificity of 83.3% (p = 0.002). For plasma ADA2 activ-
ity, the best cut-off was fixed at 2.745 U/L, with an AUC 
of 1.00 (95% CI 1.000–1.000), sensitivity of 100.0% and 
specificity of 100.0% (p < 0.001).
Differentiating HHZ from HC
To evaluate the diagnostic accuracy of these labora-
torial parameters in differentiating HHZ from HC, an 
ROC curve was also employed (Fig. 3b) and statistical 
parameters are shown in Table 3. For serum IgM levels, 
the ROC curve was not statistically different from the 
reference curve (p = 0.225). Conversely, for plasma 
ADA2 activity, ROC curve analysis fixed the best cut-
% & ' ( ) * + , + ' ( - * . / 0 , 1 2 3 / 34 5 ' 6 * / - * + ( 1 ' ( ) * + , + ' ( - * . 7 4 8 + * 9 . / , 6 - 3 ( ) : ; - ;< 3 + 3 - 6 * , 6 - . / - * * 6 ' ( ) * + , + ' ( * /= & / 1 + > + ? 1 / ' ( ) * + , + ' ( - * .
% 5 @ ; - ; ' ( * + / - * . 5 A B A B % ' ( * + / - * . = C C D & < C EFig. 1. Study profile. SnS, Sneddon’s syn-drome; PSnS, primary SnS; DADA2, defi-ciency of adenosine deaminase 2; HHZ, healthy CECR1 heterozygous; HC, healthy 
controls; CECR1, cat eye syndrome chro-
mosome region candidate 1 gene.
Table 1. Demographic and clinical characteristics of the cohort studied
Variable Total population PSnS DADA2 HHZ HC
Patients, n 73 26 6 7 34
Age, years, mean ± SD 41.45±11.02 45.12±9.78 41.67±12.09 32.00±13.87 40.56±10.24
Gender, male 23 (31.5) 4 (15.4) 3 (50.0) 4 (57.1) 12 (35.3)
Hypertension 21 (28.8) 11 (42.3) 3 (50.0) 0 (0.0) 7 (20.6)
Diabetes mellitus 7 (9.6) 3 (11.5) 0 (0.0) 1 (14.3) 3 (8.8)
Dyslipidemia 21 (28.8) 12 (46.2) 1 (16.7) 1 (14.3) 7 (20.6)
Smoking 15 (20.5) 9 (34.6) 0 (0.0) 0 (0.0) 6 (17.6)
Alcoholism 9 (12.3) 3 (11.5) 1 (16.7) 0 (0.0) 5 (14.7)
LR 32 (43.8) 26 (100.0) 6 (100.0) 0 (0.0) 0 (0.0)
Raynaud phenomenon 12 (16.4) 7 (26.9) 2 (33.3) 0 (0.0) 3 (8.8)
Migraine 26 (35.6) 7 (26.9) 6 (100.0) 3 (42.9) 10 (29.4)
Recurrent fever 7 (9.6) 2 (7.7) 5 (83.3) 0 (0.0) 0 (0.0)
Stroke 29 (39.7) 26 (100.0) 4 (66.7) 0 (0.0) 0 (0.0)
Data is represented as n (%), except when indicated otherwise.
PSnS, primary Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 2; HHZ, healthy CECR1 heterozygous; HC, healthy 
controls; CECR1, cat eye syndrome chromosome region candidate 1 gene; LR, livedo reticularis/racemosa.
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off at 3.77 U/L, with an AUC of 0.971 (95% CI 0.923–
1.000), sensitivity of 97.1% and specificity of 85.7% (p < 
0.001).
Discussion
In the present study, we found that in adult SnS patients, 
plasma ADA2 activity was significantly lower in DADA2 in 
comparison with PSnS patients. An extremely low, or even 
absent, activity of ADA2 in paediatric patients with DADA2 
had previously been shown in other studies [13–15]. These 
authors have previously shown a statistically significant dif-
ference between ADA2 activity in DADA2 patients in com-
parison to HC, but the relation with sporadic patients ex-
hibiting a similar clinical phenotype was not tested. In fact, 
the diagnostic accuracy of ADA2 activity in differentiating 
DADA2 from sporadic PSnS in adults had never been in-
vestigated. In our study, we show that, at the best cut-off of 
2.745 U/L, plasma ADA2 activity distinguished DADA2 
patients from PSnS with 100% sensitivity and 100% speci-
ficity, which suggests that it fits perfectly as a diagnostic test.
F G HI G JI G HK G JK G HH G JH L M N M O P O P I Q Q R Q SH G T JU V
W XYZ[\] ^V_̀
F HI JI HK JK H JH L M N M O P O P I Q Q R Q Sabac de
fg hgf i jkl dY]d ^m_̀
n o
Fig. 2. a Serum IgM concentration in patients with PSnS and 
DADA2 patients, HHZ and HC. Box plots show 10th, 25th, 50th, 
75th and 90th percentiles; the dots represent outliers. Gray line, 
cut-off level for differentiating PSnS from DADA2 patients; (b) 
Plasma ADA2 activity in patients with PSnS and DADA2 patients, 
HHZ and HC. Box plots show 10th, 25th, 50th, 75th and 90th per-
centiles; the dots represent outliers. Gray line, cut-off level for dif-
ferentiating PSnS from DADA2 patients and HHZ from HC; PSnS, 
primary SnS; DADA2, deficiency of adenosine deaminase 2; HHZ, 
healthy CECR1 heterozygous; HC, healthy controls; CECR1, cat 
eye syndrome chromosome region candidate 1 gene; ADA2, ade-
nosine deaminase 2; IgM, immunoglobulin M.
Table 2. ADA-T, ADA2 and ADA1 activity in plasma and serum IgM concentration of the studied population
PSnS DADA2 p value,
PSnS vs. DADA2
HHZ HC p value,
HHZ vs. HC 
Patients, n 26 6 – 7 34 –
ADA-T, U/L 14.5±5.4 4.0±1.6 <0.001 7.8±2.9 12.5±3.3 0.004
ADA2, U/L 10.3±4.6 0.1±0.2 <0.001 3.0±1.4 8.9±3.3 <0.001
ADA1, U/L 4.2±1.2 3.9±1.6 0.847 4.8±1.9 3.6±1.3 0.089
IgM, g/L 1.3±0.7 0.5±0.3 0.003 0.9±0.5 1.1±0.5 0.225
Data is shown as mean ± SD.
ADA-T, total ADA activity in plasma; ADA2, ADA2 activity in plasma; ADA1, ADA1 activity in plasma; ADA, adenosine deami-
nase; PSnS, primary Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 2; HHZ, healthy CECR1 heterozygous; HC, 
healthy controls; CECR1, cat eye syndrome chromosome region candidate 1 gene; ADA1, adenosine deaminase 1; ADA2, adenosine 
deaminase 2; IgM, immunoglobulin M.
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Although the pathogenesis of DADA2 is still unclear, 
there is some evidence that the underlying mechanism 
involves the loss-of-function mutations in CECR1 encod-
ing the ADA2 protein [5]. ADA2 is known to be produced 
by myeloid cells and is a growth factor for endothelial and 
leukocyte development [4]. In fact, despite CECR1 not 
being expressed in the endothelium, DADA2 leads to a 
defect in endothelial instability and integrity [16] in the 
small and medium vessels of patients with ADA2 muta-
tions as well as impairment of M2 macrophage differen-
Table 3. AUC, sensitivity, specificity, and positive and negative predictive values for receiver operating charac-
teristic curves using best laboratorial tests
PSnS vs. DADA2 HHZ vs. HC
ADA2 activity in plasma, U/L
AUC (95% CI) 1.00 (1.00–1.00) 0.971 (0.923–1.00)
Sensitivity, % 100 97.1
Specificity, % 100 85.7
PPV, % (95% CI) 100 (100.0–100.0) 71.4 (38.1–91.0)
NPV, % (95% CI) 100 (100.0–100.0) 97.7 (87.8–99.6)
Accuracy, % (95% CI) 100 94.1 (83.8–98.8)
Serum IgM concentration, g/L
AUC (95% CI) 0.901 (0.767–1.000) 0.647 (0.386–0.908)
Sensitivity, % 85.2 67.6
Specificity, % 83.3 71.4
PPV, % (95% CI) 83.3 (40.2–97.4) 71.4 (35.5–91.9)
NPV, % (95% CI) 85.2 (73.4–92.3) 67.6 (59.6–74.8)
Accuracy, % (95% CI) 84.8 (68.1–94. 9) 68.3 (51.5–86.7)
PSnS, primary Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 2; HHZ, healthy CECR1 
heterozygous; HC, healthy controls; CECR1, cat eye syndrome chromosome region 1 gene; AUC, area under the 
curve; ADA2, adenosine deaminase 2; PPV, positive predictive value; NPV, negative predictive value; IgM, im-
munoglobulin M.
p q
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Fig. 3. ROC curve for laboratorial parameters. a PSnS vs. DADA2 
patients: plasma ADA2 activity (black line) and serum IgM concen-
tration (grey line); (b) HHZ vs. HC: plasma ADA2 activity (black 
line) and serum IgM concentration (grey line). PSnS, primary 
Sneddon’s syndrome; DADA2, deficiency of adenosine deaminase 
2; HHZ, healthy CECR1 heterozygous; HC, healthy controls.
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tiation [4]. Once secreted, it induces the differentiation of 
monocytes into macrophages, possibly by binding pro-
teoglycan-like structures on the cellular surface [17]. 
Moreover, ADA2 seems to be involved in the balance be-
tween pro-inflammatory (M1) and anti-inflammatory 
(M2) monocytes. Its absence has been associated with a 
defect in differentiation of M2 macrophages, which leads 
to a prevalence of pro-inflammatory M1 cells [18], estab-
lishing a vicious circle of vasculopathy and inflammation 
[4].
As previously stated, a mild immunodeficiency can 
also be observed in DADA2, and indeed, very recently, 
Schepp et al. [19] suggested that patients with antibody 
deficiency should be screened for DADA2. Some patients 
present hypogammaglobulinemia that may affect IgM or 
all Ig subclasses [18]. In our study, for serum IgM levels, 
at the best cut-off of 0.65 g/L, the AUC to differentiate 
between DADA2 and sporadic PSnS patients was 0.904 
with a sensitivity of 85.2%, and specificity of 83.3%, which 
suggests that it has an excellent diagnostic accuracy.
These results are particularly relevant, since recent ob-
servational studies have reported that some drugs (anti-
TNF-α with or without daily prednisolone and/or an al-
ternative disease modifying anti-rheumatic drug) [14] 
seem to be effective, and hematopoietic stem cell trans-
plantation might represent a potential definitive treat-
ment for DADA2 [16].
It should also be mentioned that, although the clinical 
phenotype of monoallelic CECR1 mutated subjects is not 
clear, some authors report a full picture of a DADA2-like 
disease in some of those individuals [18]. This was not the 
case for individuals found in this study as heterozygous 
carriers of CECR1 mutations. It is possible though that 
these subjects will come to develop some features of the 
disease as they age.
In the present study, for plasma ADA2 activity, at the 
best cut-off of 3.77 U/L, the AUC for differentiating be-
tween HHZ and HC was 0.971, with a sensitivity of 97.1% 
and a specificity of 85.7%, which corresponds to an al-
most perfect test. Other studies have reported on ADA2 
activity in CECR1 single-mutation carriers, and while 
some authors showed a reduction to approximately half 
[4, 19] other reported no difference in relation to HCs [5, 
14]. Meanwhile, for serum IgM levels, at the best cut-off 
of 0.92 g/L, AUC was 0.647 (p = 0.225, 95% CI 0.386–
0.908), with a sensitivity of 67.6%, and specificity of 71.4 
%, which suggests that this test does not accurately iden-
tify CECR1 heterozygous.
Our study has some important strengths. First, it was 
prospectively designed and the procedures of screening 
and confirmation were standardized according to the 
protocol. Second, the plasma ADA2 activity and the se-
rum IgM measurements were determined in all subjects 
and each of the tests was performed by the same raters, 
using the same method and under equal technical condi-
tions. Third and the most relevant, we tried to establish, 
for the first time, the accuracy of these laboratorial tests 
to distinguish between adult DADA2 and PSnS but also 
to differentiate HHZ individuals from HCs, together with 
the optimal cut-off points. Notwithstanding, these find-
ings should be confirmed in larger multicentre studies, 
that would encompass both adult and paediatric DADA2 
patients. As other authors have reported, ADA2 activity 
might be lower in adults that in children [4, 14] and an 
age-adjusted cut-off value would probably be needed. In 
our study, as in the study of Schepp et al. [19], there was 
no evidence of an influence of the position and type of 
mutation on ADA2 enzymatic activity. However, this 
should also be confirmed by the inclusion of patients with 
other CECR1 mutations.
This study also has some limitations. As it is presum-
ably a rare disorder, the number of patients with bi-al-
lelic and heterozygous mutations was low, which might 
have biased the data interpretation. For the same rea-
son, we did not perform genetic testing in healthy vol-
unteers.
In conclusion, serum IgM measurement has a poten-
tial role as a primary screening tool and plasma ADA2 
activity might be an excellent diagnostic test for DADA2 
in patients with SnS of unknown cause, making them 
suitable for implementation in clinical practice. ADA2 
activity in plasma also provides high accuracy to identify 
CECR1 heterozygous individuals.
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